Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity.

Pharmacogenomics - 1 Jan 2024

Wang Chong, Hwang Mary, Paulson Brandon, Mhandire Doreen, Ozair Sadat, O'Connor Tracey L, Gandhi Shipra, Attwood Kristopher M, Hertz Daniel L, Goey Andrew Kl

Abstract excerpt

Aim: This study evaluated associations between CYP3A4*22 and variants in other pharmacogenes (CYP3A5, SULT2A1, ABCB1, ABCG2, ERCC1) and the risk for palbociclib-associated toxicities.Materials & methods: Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively.Results: No significant associations were found for CYP3A4*22,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arylsulfotransferase

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Neoplasm Proteins

Share to Neoplasms

Share to Piperazines

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 39092502
DOI: 10.1080/14622416.2024.2380240
PMCID: PMC11418216

Genes

ABCG2
SULT2A1
CYP3A4
CYP3A5
ABCB1
ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity.PMID 39092502Read ↗

ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read ↗

Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity Read ↗

Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Semantic proximity Read ↗

ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read ↗

Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs.Semantic proximity Read ↗

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.Semantic proximity Read ↗

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.Semantic proximity Read ↗

ABCG2 genetic variant as a predictor of severe neutropenia in Japanese patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with palbociclib: an exploratory real-world studySemantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.Semantic proximity Read ↗

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.Semantic proximity Read ↗

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.